First presentation of top-line efficacy and safety results from the Phase 4 DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) trial of adults with narcolepsy or idiopathic hypersomnia For U.S. media and investors only DUBLIN , Oct. 31, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that eight abstracts presenting data from across i...
DUBLIN , Oct. 23, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 third quarter financial results on Wednesday, November 6, 2024, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m.
Ardent value investor Seth Klarman is swapping out shares of search engine juggernaut Alphabet for a relatively unknown pharmaceutical stock that has a forward price-to-earnings ratio of 5!
Shares of Jazz Pharmaceuticals are trading only slightly higher in the last few weeks despite two unexpected wins. The partial legal win against Avadel helps protect Jazz's market position in idiopathic hypersomnia through 2036 and Jazz should also receive royalties on net sales of Lumryz. The unexpected phase 3 trial win of Zepzelca in combination with Tecentriq could add more than $400-500 mi...
Jazz plans to submit supplemental New Drug Application in first half of 2025 for this combination therapy as a first-line maintenance treatment for ES-SCLC DUBLIN , Oct. 15, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive top-line results from the Phase 3 clinical trial evaluating Zepzelca® (lurbinectedin) in combination with the PD-L1 inhibitor atezolizuma...
Jazz Pharmaceuticals (JAZZ, Financial), a leading player in the narcolepsy market, is expanding its reach into other markets such as the non-small cell lung cancer (NSCLC) market by preparing a new biliary tract cancer drug; Zanidatamab.
Phase 2 updated results for zanidatamab in HER2-positive mGEA included a confirmed objective response rate (cORR) of 84%, duration of response (DoR) of 18.7 months, median progression-free survival (mPFS) of 15.2 months and a Kaplan-Meier–es ti mated overall survival (OS) of 59% at 30 months DUBLIN , Sept. 16, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced updated ...
New and updated data from an ongoing Phase 2 trial of zanidatamab, an investigational dual HER2-targeted bispecific antibody, in combination with chemotherapy for first-line treatment of HER2-positive metastatic gastroesophageal adenocarcinoma (mGEA) DUBLIN , Sept. 9, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company, along with its partners, will pre...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.